Stance Capital LLC Invests $1.36 Million in Medtronic PLC $MDT

Stance Capital LLC bought a new position in shares of Medtronic PLC (NYSE:MDT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,290 shares of the medical technology company’s stock, valued at approximately $1,361,000.

Other large investors have also recently bought and sold shares of the company. Corundum Trust Company INC purchased a new stake in Medtronic during the 3rd quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the 3rd quarter worth about $29,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic in the 2nd quarter valued at about $27,000. Imprint Wealth LLC purchased a new position in shares of Medtronic in the 3rd quarter valued at about $31,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medtronic during the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Citigroup started coverage on shares of Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective on the stock. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Leerink Partners reaffirmed an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a research report on Tuesday, March 10th. Finally, Barclays reiterated an “overweight” rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $88.50 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The stock has a 50 day moving average of $97.54 and a two-hundred day moving average of $96.85. The stock has a market cap of $113.62 billion, a P/E ratio of 24.65, a P/E/G ratio of 2.26 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).